Expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKBA:
- Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Options Volatility and Implied Earnings Moves Today, August 25, 2023
- Notable companies reporting before tomorrow’s open
- Akebia expects to resubmit vadadustat NDA in Q3
- Akebia backs 2023 Auryxia net product revenue view of $175M-$180M